Across TCGA pan-cancer cohorts, P4HB Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated P4HB data layer compared with 29 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher P4HB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated P4HB expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LUAD, PRAD, and UCEC are the cancer types where P4HB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.090	0.709	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	DFS	Median	III,IV	0.806	0.268	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: P4HB tumor-vs-normal RNA expression · all P4HB data types